AU2021401137B2 - Pharmaceutical composition of glp-1/glp-2 dual agonists - Google Patents

Pharmaceutical composition of glp-1/glp-2 dual agonists Download PDF

Info

Publication number
AU2021401137B2
AU2021401137B2 AU2021401137A AU2021401137A AU2021401137B2 AU 2021401137 B2 AU2021401137 B2 AU 2021401137B2 AU 2021401137 A AU2021401137 A AU 2021401137A AU 2021401137 A AU2021401137 A AU 2021401137A AU 2021401137 B2 AU2021401137 B2 AU 2021401137B2
Authority
AU
Australia
Prior art keywords
glp
composition
concentration
aspects
dual agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021401137A
Other languages
English (en)
Other versions
AU2021401137A1 (en
Inventor
Lise GIEHM
Jesper Skodborg VILLADSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of AU2021401137A1 publication Critical patent/AU2021401137A1/en
Application granted granted Critical
Publication of AU2021401137B2 publication Critical patent/AU2021401137B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2021401137A 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists Active AU2021401137B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20214558.7 2020-12-16
EP20214558 2020-12-16
PCT/EP2021/086148 WO2022129312A1 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Publications (2)

Publication Number Publication Date
AU2021401137A1 AU2021401137A1 (en) 2023-06-08
AU2021401137B2 true AU2021401137B2 (en) 2024-09-05

Family

ID=74141273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021401137A Active AU2021401137B2 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Country Status (13)

Country Link
US (1) US20230405088A1 (https=)
EP (1) EP4262746A1 (https=)
JP (1) JP2023553563A (https=)
KR (1) KR20230121824A (https=)
CN (1) CN116723850A (https=)
AU (1) AU2021401137B2 (https=)
CA (1) CA3196989A1 (https=)
CL (1) CL2023001745A1 (https=)
IL (1) IL301891A (https=)
MX (1) MX2023006280A (https=)
TW (1) TW202241491A (https=)
WO (1) WO2022129312A1 (https=)
ZA (1) ZA202304233B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
IL301892A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
JP2024533153A (ja) * 2021-09-03 2024-09-12 ジーランド ファーマ エー／エス 投薬レジーム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095406A1 (en) * 2013-12-18 2015-06-25 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2018104561A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
KR20200080331A (ko) * 2012-07-23 2020-07-06 질랜드 파마 에이/에스 글루카곤 유사체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
UA95235C2 (en) * 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
IN2015DN00544A (https=) * 2012-07-23 2015-06-26 Zealand Pharma As
JP6822839B2 (ja) * 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200080331A (ko) * 2012-07-23 2020-07-06 질랜드 파마 에이/에스 글루카곤 유사체
WO2015095406A1 (en) * 2013-12-18 2015-06-25 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2018104561A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists

Also Published As

Publication number Publication date
WO2022129312A1 (en) 2022-06-23
US20230405088A1 (en) 2023-12-21
KR20230121824A (ko) 2023-08-21
CN116723850A (zh) 2023-09-08
CL2023001745A1 (es) 2024-01-19
TW202241491A (zh) 2022-11-01
ZA202304233B (en) 2025-08-27
IL301891A (en) 2023-06-01
AU2021401137A1 (en) 2023-06-08
MX2023006280A (es) 2023-06-13
JP2023553563A (ja) 2023-12-22
EP4262746A1 (en) 2023-10-25
CA3196989A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
AU2020293576B2 (en) Pharmaceutical parenteral composition of dual GLP1/2 agonist
AU2021401137B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
AU2021399904B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
EP4262745B1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)